



# *Mmp15* is a direct target of *Snai1* during endothelial to mesenchymal transformation and endocardial cushion development<sup>☆</sup>

Ge Tao<sup>a,b</sup>, Agata K. Levay<sup>a</sup>, Thomas Gridley<sup>c</sup>, Joy Lincoln<sup>a,d,\*</sup>

<sup>a</sup> Department of Molecular and Cellular Pharmacology, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, 33101, USA

<sup>b</sup> Graduate Program in Molecular Cell and Developmental Biology, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, 33101, USA

<sup>c</sup> Center for Molecular Medicine, Maine Medical Center Research Institute, Maine, 04074, USA

<sup>d</sup> Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, 33101, USA

## ARTICLE INFO

### Article history:

Received for publication 2 February 2011

Revised 16 August 2011

Accepted 29 August 2011

Available online 5 September 2011

### Keywords:

*Snai1*

MMP15

Endocardial cushion

Heart valve

Endothelial-to-mesenchymal transformation

## ABSTRACT

Cardiac valves originate from endocardial cushions (EC) formed by endothelial-to-mesenchymal transformation (EMT) during embryogenesis. The zinc-finger transcription factor *Snai1* has previously been reported to be important for EMT during organogenesis, yet its role in early valve development has not been directly examined. In this study we show that *Snai1* is highly expressed in endothelial, and newly transformed mesenchyme cells during EC development. Mice with targeted *snai1* knockdown display hypocellular ECs at E10.5 associated with decreased expression of mesenchyme cell markers and downregulation of the matrix metalloproteinase (mmp) family member, *mmp15*. *Snai1* overexpression studies in atrioventricular canal collagen I gel explants indicate that *Snai1* is sufficient to promote *mmp15* expression, cell transformation, and mesenchymal cell migration and invasion. However, treatment with the catalytically active form of MMP15 promotes cell motility, and not transformation. Further, we show that *Snai1*-mediated cell migration requires MMP activity, and caMMP15 treatment rescues attenuated migration defects observed in murine ECs following *snai1* knockdown. Together, findings from this study reveal previously unappreciated mechanisms of *Snai1* for the direct regulation of MMPs during EC development.

© 2011 Elsevier Inc. All rights reserved.

## Introduction

Development of heart valve structures is a complex process involving multiple molecular pathways that modulate cardiac morphogenesis (Combs and Yutzey, 2009; Srivastava, 2000). Alterations in these genetic networks during embryogenesis frequently lead to structural defects, malformation and congenital heart disease (CHD) in approximately 1% of all live births (Hoffman and Kaplan, 2002). These commonly include valvular and septal defects that often require multiple corrective surgical procedures, or result in death in utero, childhood, or infancy (Lloyd-Jones et al., 2010). Despite the clinical significance, the intersecting regulatory pathways required for normal heart valve formation, and their genetic contributions to CHD are not complete. Understanding the structure–function relationship of genes important during embryonic valvulogenesis will provide insights into genetic causes of CHD associated with structural valve defects and dysfunction.

Heart valve formation is initiated in the atrioventricular canal (AVC), outflow tract (OFT) regions around embryonic day (E) 9.5 in the mouse

and E3.0 in the chicken, following expansion of existing cardiac jelly and formation of endocardial cushions (ECs) (Combs and Yutzey, 2009; Person et al., 2005). ECs are reservoirs for a heterogeneous population of precursor cells that later remodel and give rise to the mature, and highly diversified heart valve structures (Lincoln et al., 2004). The cellular and molecular processes required for EC formation are critical to normal valve development and require endothelial-to-mesenchymal transformation (EMT) (Person et al., 2005). The EMT program involves several phenotypic changes of endothelial cells and is not restricted to ECs, but critical for the development of many tissues during embryogenesis (Barrallo-Gimeno and Nieto, 2005). In developing ECs, EMT initiation is characterized by delamination of a subset of endothelial cells overlying the future valve site following down regulation of adhesion molecules and lost cell–cell contacts (Person et al., 2005; Thierry et al., 2009). Subsequently, endothelial cells break away from their neighbors, transform into mesenchymal cells and acquire motile properties, allowing invasion and migration through the matrix-rich cardiac jelly (Person et al., 2005). Once migrated, these highly proliferative mesenchymal cells populate the ECs and form elongated valve primordia that continue to grow and elongate into mature leaflets and chordae tendinae in the AV valves and cusps in the OFT and pulmonic regions (Hinton et al., 2006; Lincoln et al., 2004, 2006b). Numerous signaling pathways have been shown to regulate EC EMT (Armstrong and Bischoff, 2004; Combs and Yutzey, 2009; Person et al., 2005). These include growth factors

<sup>☆</sup> Grant information: NIH/NHLBI R01HL91878 (JL). AHA Predoctoral Fellowship 10PRE4360052 (GT).

\* Corresponding author at: 1600 NW 10th Avenue, RMSB 6048 (R189), Miami, FL, 33136, USA. Fax: +1 305 243 4555.

E-mail address: [jlincoln@med.miami.edu](mailto:jlincoln@med.miami.edu) (J. Lincoln).

emanating from the adjacent myocardium including bone morphogenic proteins (Bmp) and transforming growth factors (Tg $\beta$ ), as well as more localized signaling from Wnt- and Notch-related pathways (Armstrong and Bischoff, 2004; Combs and Yutzey, 2009; Person et al., 2005). Targeted mutations in receptors, ligands or downstream mediators of these pathways have previously been shown to have detrimental effects on EC development and embryo survivability (Combs and Yutzey, 2009; Person et al., 2005), highlighting the importance of the EMT process for normal heart valve formation and cardiac function.

Members of the Snail family of transcription factors including *snai1* (*snail*), and *snai2* (*slug*) have previously been shown to play major roles in EMT in many developmental systems during embryogenesis, although direct roles for *snai1* in the heart have not been examined (Cano et al., 2000; Niessen et al., 2008). *Snai1*<sup>-/-</sup> mutant mice die early in gestation due to defective gastrulation and mesoderm formation as cells fail to migrate because they cannot undergo EMT (Carver et al., 2001). Parallel studies have revealed that *snai1* positively regulates EMT by directly repressing cell adhesion genes including *E-cadherin* (Battle et al., 2000; Cano et al., 2000), *claudins* and *occludins* (Ikenouchi et al., 2003; Martinez-Estrada et al., 2006) and therefore cell–cell contacts are adversely maintained in *snai1* mutant mice. In the absence of *snai1*, compensation by the homologous family member *snai2* is not sufficient to rescue the lethal phenotype (Carver et al., 2001). Although *snai2*<sup>-/-</sup> mice are viable as a result of *snai1* compensation (Jiang et al., 1998; Murray et al., 2007) and reports describe impaired cell migration and transformation in ECs (Niessen et al., 2008; Romano and Runyan, 1999). However, as one might expect, compensatory increases in *snai1* expression are sufficient to rescue the reduced EC cellularization observed in embryonic *snai2*<sup>-/-</sup> mice (Niessen et al., 2008). Together, these studies highlight the importance of Snail family members during EMT and embryonic development.

In this study we aim to determine the direct role of Snai1 during EC formation using a mouse model with conditional reduced *snai1* function and established in vitro systems. We demonstrate that Snai1 is highly expressed in overlying endothelial cells and transformed mesenchymal cells within the developing ECs, although expression is significantly downregulated during later, post-EMT stages of valvulogenesis. Mice with conditional heterozygous loss of *snai1* in endothelial-derived cells (*Tie2cre;Snai1*<sup>f/+</sup>) display fewer cells within the cardiac jelly of developing ECs, associated with reduced expression of mesenchymal gene markers. In addition, AVC regions from *Tie2cre;Snai1*<sup>f/+</sup> mice at E10.5, express significantly lower levels of the matrix metalloproteinase (mmp), *mmp15* (MT2-MMP). Using the established collagen I gel explant assays (Bernanke and Markwald, 1982; Lincoln et al., 2006a; Runyan and Markwald, 1983), we show that treatment of AVC explants with adenovirus-targeting Snai1 (AdV-Snai1) promotes *mmp15* expression and several EMT processes including cell transformation, invasion and migration. In contrast, treatment with a catalytically active MMP15 protein (caMMP15) promotes only cell motility. Further, pharmacological inhibition of MMP activity prevents Snai1-mediated mesenchyme cell migration, while caMMP15 treatment is sufficient to rescue attenuated migration phenotypes observed in AVC explants with targeted *snai1* knockdown. Additional co-immunoprecipitation and luciferase assays indicate that Snai1 binds, and transactivates E-box-rich regions within *mmp15*. However, in the presence of the E2A family member, E47, Snai1 repress *mmp15*. Together, these studies support a direct role for Snai1 in EC development, and identify previously unappreciated mechanisms of *mmp15* activity, regulated by *snai1*, for cell motility during EC EMT.

## Materials and methods

### Histological analysis

Whole mouse and chicken embryos staged at embryonic day (E) 10.5 (mouse) and Hamburger Hamilton stage (HH St.) 14 (E2.5–3.0)

were collected in 1× Phosphate Buffered Saline (PBS) and either fixed in 4% paraformaldehyde (PFA) overnight at 4 °C or left unfixed. Fixed tissues were subsequently processed for paraffin embedding and 6  $\mu$ m tissue sections were cut as previously described (Lincoln et al., 2006a). Alternatively, unfixed tissue was immediately processed for frozen block cryoembedding (Lincoln et al., 2006a) and 12  $\mu$ m tissue sections were cut. For colorimetric and fluorescent immunohistochemistry, fixed tissue sections were processed (Lincoln et al., 2007) and incubated overnight at 4 °C with primary antibodies against Snai1 (Abcam, 1:500), Smooth Muscle  $\alpha$ -Actin ( $\alpha$ SMA) (Invitrogen, 1:500), and Phospho-histone H<sub>3</sub> (Upstate, 1:200). In contrast, unfixed frozen sections were post fixed in ice-cold acetone at –20 °C for 15 min, blocked in 5% bovine serum albumin/1×PBS for 30 min and incubated with anti-matrix metalloproteinase 15 (Mmp15) (Abcam, 1:200) for 2 h at room temperature. Antigen retrieval was used for the detection of Snai1, Mmp15 and Phospho-histone H<sub>3</sub> by boiling tissue sections in unmasking solution (Vector Labs) for 10 min and allowing to cool to room temperature prior to blocking. Detection using diaminobenzidine (DAB) was performed according to the manufacturer's instructions (ABC staining system, Santa Cruz Biotechnology) and visualized on an Olympus BX51 microscope. Immunofluorescent staining was performed using appropriate secondary antibodies (Alexa-Fluor) and captured using Olympus Fluoview F-1000 confocal microscope. Alcian blue staining was performed on paraffin tissue sections from E10.5 and E13.5 *Tie2cre;Snai1*<sup>f/+</sup> embryos and counter-stained with nuclear fast red solution as previously reported (Lincoln et al., 2007).

### Generation of adenoviruses

Full-length FLAG-tagged mouse *snai1* cDNA was generated by PCR amplification from E14.5 mouse limb template and ligated into the pShuttle-IRES-hrGFP-1 vector (Stratagene). In parallel, a control adenoviral construct was generated with no cDNA insert (AdV-GFP). Adenovirus generation and titration were performed according to the manufacturer's instructions using the AdEasy XL and AdEasy Viral Titer kits respectively (Stratagene). For AdV-Snai1 and AdV-GFP, infection efficiency was determined by counting the number of GFP-positive cells over the number of DAPI-positive nuclei in at least 5 microscopic fields (n = 4). The AdV-cre was generated as previously described (Peacock et al., 2010) and *snai1* knockdown in infected AVC explants from *Snai1*<sup>f/f</sup> mice was determined by qPCR using Taqman primers against mouse Snai1 (Applied Biosystems).

### Endocardial cushion cell culture

**2D-Monolayer cell culture:** AVC ECs were dissected from E4.5 white leghorn chicken eggs (Charles River Laboratories) and E11.5 *Snai1*<sup>f/f</sup> mouse embryos, trypsinized and cultured for 48 h as a monolayer prior to treatment as described (Lincoln et al., 2006a).

**3D-collagen gel I explant culture:** AVC explants were collected from HH St. 14, and E5.0 chicks, and E11.5 *Snai1*<sup>f/f</sup> mouse embryos and placed lumen-side down on 3D-collagen I gels for 2 h prior to treatment as previously described (Inai et al., 2008) (n = 5–8).

Following initial culturing, monolayer cells or explants were infected with  $3 \times 10^6$  and  $2 \times 10^7$  PFU adenovirus respectively, expressing *Snai1* (AdV-Snai1), Cre (AdV-Cre) (Peacock et al., 2010) or GFP (AdV-GFP) diluted in serum-free culture media (Lincoln et al., 2006a) for 2 h. Following infection, fresh serum-free media was added and cells/explants were cultured for a further 48 h (2D and 3D cultures mouse culture systems) or 72 h (2D avian culture system). Alternatively, explants were treated with recombinant protein of the catalytic domain of MMP15 (caMMP15) (Chemicon/Millipore) at a final concentration of 1  $\mu$ g/mL in serum-free media for 36 h (AVC 3D culture of E5.0 chicken embryos) or 48 h (AVC 3D culture of HH St. 14 chicken embryos). For controls, explants were treated with serum-free media alone. For MMP inhibition studies, explants were subject to 2  $\mu$ g/mL, 10  $\mu$ g/mL and 20  $\mu$ g/mL

GM6001 (Millipore) or dimethyl sulfoxide (DMSO) in the presence of either  $2 \times 10^7$  PFU AdV-GFP or AdV-Snai1 for 36 h. Following treatment, cells/explants were fixed in 4% PFA and subject to IHC or collected for mRNA extraction isolation (dissociated cell culture). To determine the area covered by migrating cells, 2D images were taken with an Olympus SZX7 and the total pixel counts of each cultured AVC explant was measured using ImagePro Plus software ( $n=5-8$ ). To quantify the number of invading cells, immunostained 3-D collagen I gels were captured using an Olympus Fluoview F-1000 confocal microscope and Z-stack images were generated from multiple focal planes sections captured at 5  $\mu$ m intervals down to the furthest distance of invasion using Image J software. The fold change in cell invasion and maximal invading depth was calculated using ImagePro Plus software by counting the total pixel number and distance in Z-stacked images. Statistical significance over respective controls was determined using Student's *t*-test ( $p<0.05$ ) ( $n=5$ ).

#### mRNA isolation, cDNA generation and quantitative PCR

Total mRNA was isolated from cultured monolayer EC cells as well as from E10.5 AVC regions from *Tie2cre;Snai1<sup>fl/+</sup>* and *Snai1<sup>fl/+</sup>* mice using TRIzol (Lincoln et al., 2007). 200–400 ng of mRNA was used to generate cDNA using the high-capacity cDNA kit (Applied Biosystems) (Peacock et al., 2008). cDNA was subject to quantitative PCR amplification (StepOne Plus, Applied Biosystems) using specific primers targeting chicken *vimentin* (Forward: CCGACAGGATGTTGACAATG; Reverse: GGATGTGCTGTTCTGGAGT),  $\alpha$ SMA (Forward: CACCAACTCTGCTGACTGA; Reverse: ACACCATCCCAGAGTCAAG), *VE-cadherin* (Forward: ATCTCAGACAACGGCAATCC; Reverse: GAAAATTGCACACAGTGCTT), *claudin1* (Forward: GGAGGATGACCAAGGTGAAGA; Reverse: TCTGGTGTTAACGGGTGTGA), *fibronectin1* (Forward: CGTTCGTC TCACTGGCTACA; Reverse: ATTAATCCGACACGACAGC), *mmp15* (Forward: TGTCCGGGAACAACCTCTTC; Reverse: TTCTCCGTGTCATCCACTG) and *GAPDH* (Forward: GGGTCTTATGACCACTGTCC; Reverse: GTAAGCTT CCCATTGAGCTCAG), or mouse *fibronectin1* (Forward: GGTTCCTTGACGATGATA; Reverse: TGAGCTGAACACTGGGTGCT),  $\alpha$ SMA (Forward: CTGACAGAGGCACCACTGAA; Reverse: CATCTCCAGAGTCCAGCACA), *VE-cadherin* (Forward: ACCGAGAGAAACAGGCTGAA; Reverse: AGACGGGGAA GTTGTGATTG), *E-cadherin* (Forward: CAAGGACAGCCTTCTTTTCG; Reverse: TGGACTTCAGCGTCACTTTG), *snai1* (Forward: TGAGAAGCCATTCT CCTGCT; Reverse: GCCAGACTCTTGGTCTGT), *mmp15* (Forward: GAC CAGTATGGCCCCAATC; Reverse: CCAATTGGCATGGGGTAGTT) and *L7* (Forward: GAAGCTCATCTATGAGAAGGC; Reverse: AAGACGAAGGAGCT GCAGAAC). Also, Taqman probes (Applied Biosystems) were used to targeting mouse *snai1*. Alternatively, E10.5 mouse AVC cDNA was subject to SuperArray PCR analysis (PAMM-013C-12, SABiosciences) according to the manufacturer's instructions ( $n=5$ ). Following PCR analyses, the cycle count (Ct) was normalized to at least one housekeeping gene (*GAPDH* chicken, *L7* mouse, the mean Ct of *GAPDH*, *Gusb*, *Hsp90ab1*) and the  $\Delta$ Ct and fold changes in experimental samples over controls were determined as described (Peacock et al., 2008). In addition, the mesenchymal to endothelial gene expression ratio in E10.5 mouse AVC cDNA was determined by subtracting the average  $\Delta$ Ct of endothelial (*VE-cadherin*, *E-cadherin*) from mesenchymal gene expression (*fibronectin1*,  $\alpha$ SMA) ( $n=4$ ). The ratio was further calculated based upon  $\text{Power}^{(2, -\Delta\Delta\text{Ct})}$ . For absolute transcript calculation, the formula  $\text{POWER}^{(2, (40 - \Delta\text{Ct} + \text{Ct}_{L7}))}$  was used, with Ct<sub>L7</sub> denoting the average cycle count of *L7* expression levels. Statistically significant differences in transcript levels were determined using student's *t*-test on at least 3 independent experiments with  $p<0.05$  considered significant after Student *t*-test analysis.

#### Generation of mice

*Snai1<sup>fl/fl</sup>* female mice (Murray et al., 2006) were bred with *Tie2cre* males (Kisanuki et al., 2001) to generate heterozygous offspring

(*Tie2cre;Snai1<sup>fl/+</sup>*) and *Cre* negative *Snai1<sup>fl/+</sup>* littermate controls at expected Mendelian ratios. Genotyping was performed by PCR as previously described (Carver et al., 2001; Lincoln et al., 2007; Murray et al., 2006). Timed embryonic staged litters of mice were collected at E10.5 and E13.5 from *Snai1<sup>fl/fl</sup>* female mice, counting day E0.5 by evidence of a copulation plug. Embryos were either fixed or AVC tissue (E10.5) was collected for mRNA extraction. Quantitation of the number of cells within the ECs from E10.5 and E13.5 *Snai1<sup>fl/+</sup>* and *Tie2cre;Snai1<sup>fl/+</sup>* mice was determined by counting the number of DAPI-positive nuclei in at least 3 tissue sections collected from 3 to 4 mutant and control mice.

#### Chromatin immunoprecipitation (ChIP)

Six canonical E-box consensus sites were identified within the promoter region of the murine *mmp15* gene (NC\_000074.5; Chromosome: 8; Location: 8 D1; 8 45.5 cM) and conservation between mouse, rat and human was determined using the basic local alignment search tool (NCBI blast). *Snai1* binding to *mmp15* was evaluated in whole E11.5 mouse embryonic hearts (8–10 hearts per sample,  $n=3$ ). Protein/DNA complexes were cross-linked for 10 min in formaldehyde (Sigma) at a final concentration of 0.5%. Fixed tissue was lysed and sonicated three times for 20 s at 1 minute intervals (Ultrasonic cell disruptor; Microson). For ChIP, cell lysates were incubated with an antibody against *Snai1* (6  $\mu$ g; Abcam) and incubated overnight at 4 °C with gentle rocking. Immunoprecipitation with normal rabbit IgG was used as a negative control. ChIPs were performed according to the manufacturer's instructions (EZ ChIP, MilliPore). Immunoprecipitated and input DNA were subjected to qPCR using the following primers to amplify three E-box-rich regions within *mmp15*: region B (Forward: GCCACCACACCTGAATCTACTG; Reverse: GTGACTTGGGAAGC TAGGGTTG), region C (Forward: GAAGCAGGTGGATCTCTGTGAA; Reverse: TTGCCGTTGTCTAGCTGTAG) and region D (Forward: CCCCA GAGATAGGAGCTAAGCA; Reverse: CCTAACCCGAGGCTTCTCAGTA). Primers for region A were also included as a negative control as canonical E-box sites were not identified within this region: Forward: CCAGAGTCTTAATCCCACT; Reverse: TGCCCTCTACTGGTGATTCTG. Three independent ChIPs were performed and significant enrichment of E-box regions using the *Snai1* antibody over IgG control as determined by qPCR, was determined by student's *t*-test ( $p<0.05$ ).

#### Dual luciferase assays

Luciferase constructs were generated using PCR to amplify three regions (B, C, D) of the *mmp15* enhancer region (NCBI accession number NC\_000074) from mouse tail genomic DNA template, using the following primers: pGL3-*mmp15B*, forward TAGGTACCATCCCC-TACGCAAGAAAAT and reverse TGAGTCTCTCCACTCTGGAGGCACACT (970 bp). pGL3-*mmp15C*, forward TAGGTACCTCTCCCATGACCCCTT-CATC and reverse TGAGTCTCCACTGGTGACCTCTCTGT (1006 bp). pGL3-*mmp15D* forward TAGGTACCGCTGGGTGTGTAGGGTCTA and reverse TGAGTCCCCAAACCGGG TGAGAAG (973 bp). Amplified regions were gel purified and ligated into pGL3-basic (promega) using introduced Sac1 and Kpn1 sites. pcDNA-E47 and pcDNA-E12 plasmids were kindly provided by Dr. Nakamura (Funato et al., 2001).

Luciferase assays were performed in COS7 cells (ATCC) plated at  $2 \times 10^5$  per well of a 24-well plate 24 h prior to transfection with Lipofectamine reagent (Invitrogen) according to manufacturer's instructions. 200 ng of pGL3-*mmp15B*, pGL3-*mmp15C*, pGL3-*mmp15D* or empty pGL3, and 200 ng of pcDNA-E47, pcDNA-E12 or empty pcDNA, were co-transfected into each well, along with 20 ng of pGL4 (*Renilla* luciferase, Promega). All transfection were performed in 400  $\mu$ l OptiMem for 6 h before the infection of either  $3 \times 10^6$  PFU AdV-Snai1 or AdV-GFP. Cell lysates were collected 48 h following treatment according to the manufacturer's instructions for dual luciferase assays (Promega). Data is represented as an average percent of



luciferase activity in cells infected with AdV-GFP and transfected with respective plasmids compared to AdV-GFP controls. All experiments were normalized to *Renilla* activity and transfected with equal concentrations of plasmid DNA ( $n=3-4$ ).


## Results

### Reduced *snai1* function in vivo leads to hypocellular endocardial cushions at E10.5

The expression pattern of *Snai1* during endocardial cushion (EC) formation in the atrioventricular canal (AVC) was examined using immunohistochemistry (IHC) and quantitative PCR (qPCR). At E10.5, *Snai1* expression is observed in endothelial cells overlaying the ECs (arrowhead, Fig. 1A), in addition to newly transformed mesenchyme cells within the cushions (arrow, Fig. 1A). Similar expression was observed in ECs within the outflow tract regions (data not shown). Nuclear expression is also detectable within the myocardium (M, Fig. 1A). At the mRNA level, *snai1* is most highly expressed in AVC

regions at E10.5 when EMT is active, while expression is significantly reduced during post-EMT stages from E12.5 through post natal (Fig. 1B).

Although the role of *Snai1* during EMT in many systems has been established, its role during EC formation has not been directly examined. To determine this, we used the *Tie2cre* transgene to target loss of *snai1* function in endothelial, and derived mesenchymal cells of the developing ECs in vivo (de Lange et al., 2004; Lincoln et al., 2004). Homozygous *Tie2cre;Snai1<sup>fl/fl</sup>* mice were never recovered after E9.5 and likely die due to vasculature defects as described following epiblast-specific *snai1* deletion (Lomeli et al., 2009). However, heterozygous (*Tie2cre;Snai1<sup>fl/+</sup>*) mice are viable through adulthood and show a  $50\pm 17\%$  decrease in *snai1* expression in AVC regions at E10.5. Upon histological examination, *Tie2cre;Snai1<sup>fl/+</sup>* mice display significantly less cells within the AVC (Figs. 1C–E) and OFT (data not shown) ECs compared to littermate controls (*Snai1<sup>fl/+</sup>*) at E10.5. Insignificant differences in Phospho-histone H3 and cleaved caspase 3 expression suggest that hypocellular ECs observed in *Tie2cre;Snai1<sup>fl/+</sup>* mice at E10.5 was not the result of changes in cell proliferation or



**Fig. 1.** *Tie2cre;Snai1<sup>fl/+</sup>* mice have reduced cell number in endocardial cushions at E10.5. (A) Immunohistochemistry to show *Snai1* localization in endothelial cells overlaying the endocardial cushions (EC) (arrowhead) and transformed mesenchymal cells within the cushions (arrow). (B) qPCR to show fold changes in *snai1* expression in AVC regions isolated during differential stages of murine valve development. \* $p<0.05$ , statistical significance compared to E10.5, ( $n=4$ ) (C, D) Alcian blue staining on tissue sections from E10.5 control *snai1<sup>fl/+</sup>* (C) and *Tie2cre;Snai1<sup>fl/+</sup>* (D) embryos to indicate atrioventricular canal and outflow tract (OFT) endocardial cushions (EC) (arrows, C–D), ( $n=3-4$ ). (E) Quantitative analysis to show reduced number of nuclei within E10.5 AV ECs in *Tie2cre;Snai1<sup>fl/+</sup>* mice compared to controls. (F) qPCR indicates significant decreases in expression of mesenchyme cell makers (*SMA* fibronectin (*FN1*)) in *Tie2cre;Snai1<sup>fl/+</sup>* embryos compared to the controls at E10.5. (G) The ratio of mesenchymal to endothelial gene expression levels is significantly increased in *snai1* mutant mice, ( $n=4$ ). \* $p<0.05$ , statistical significance compared to controls. At, atrium; V, ventricle; EC, endocardial cushion; AVC, atrioventricular canal; OFT, outflow tract; M, myocardium.

apoptosis, respectively (data not shown, Fig. 2F). To determine changes in endothelial cell transformation in E10.5 *Tie2cre;Snai1<sup>fl/+</sup>* mice, qPCR was used to quantitatively examine expression levels of mesenchymal ( $\alpha$ SMA, fibronectin1) and endothelial (*VE-cadherin*, *E-cadherin*) cell markers in AVC regions isolated from *Tie2cre;Snai1<sup>fl/+</sup>* and control mice. Expression of mesenchymal cell markers is significantly reduced in *Tie2cre;Snai1<sup>fl/+</sup>* mice (*SMA*,  $-7.6$ -fold, *fibronectin1*,  $-7.4$ -fold), although insignificant changes were observed in endothelial markers (Fig. 1F). A consistent decrease in the ratio of mesenchymal to endothelial gene transcript levels confirms that observed decreases in mesenchymal cell marker expression were not results of decreased cell number within ECs of *Tie2cre;Snai1<sup>fl/+</sup>* mice (Fig. 1G).

Despite a significant decrease in the number of mesenchyme cells within ECs from *Tie2cre;Snai1<sup>fl/+</sup>* mice at E10.5, by E13.5, cell number is comparable to controls (Figs. 2A–C). This is associated with increased Phospho-histone H<sub>3</sub> immunoreactivity, indicative of cell proliferation in valve primordia from E13.5 *Tie2cre;Snai1<sup>fl/+</sup>* mice compared to controls (Figs. 2D–F). Collectively, these findings demonstrate that reduced *snai1* function leads to compromised EMT during early stages of EC development, however in association with increased proliferation, this phenotype recovers by later stages.


#### *Mmp15* expression is reduced in atrioventricular canal regions from E10.5 *Tie2cre;Snai1<sup>fl/+</sup>* mice

To identify downstream genes that may be affected by reduced *snai1* function in developing ECs at E10.5, a gene expression screening approach was used. This high-throughput assay (Superarray) detects quantitative changes in expression of over 84 genes associated with the extracellular matrix (ECM) in AVC regions from E10.5 *Tie2cre;Snai1<sup>fl/+</sup>* compared to *Snai1<sup>fl/+</sup>* embryos. Table 1 indicates all the genes that were differentially expressed ( $p < 0.05$ ) in the Superarray analysis. The most significant difference was observed with *mmp15* (MT2-MMP), a membrane bound matrix metalloproteinase family member decreased 5.3-fold in *Tie2cre;Snai1<sup>fl/+</sup>* embryos (Fig. 3A). Interestingly, expression of other family members including *mmps1*, 2, 3, 7–14 was not affected (data not shown). Further IHC analysis shows reduced *mmp15* protein expression in both endothelial (arrowheads,

Figs. 3B, C) and mesenchymal cells (arrows, Figs. 3B, C) within ECs, highlighted by chondroitin sulfate proteoglycan immunoreactivity (red, Figs. 3B, C). To examine *snai1* expression relative to *mmp15* during valve development, qPCR was performed using cDNA from AVC regions at E10.5, E12.5, E14.5 and post natal stages (Fig. 3D). Approximate transcript levels of *snai1* and *mmp15* showed similar temporal expression patterns throughout valve development with transcript levels being highest at E10.5 and gradually declining to post natal stages. Consistently, co-localization studies show that *snai1* and *mmp15* are both expressed in endothelial (arrowhead, Fig. 3F) and mesenchymal (arrow, Fig. 3F) cells of the valves at E13.5 (Figs. 3E, F). Although due to the expected membrane localization of *mmp15* and largely nuclear distribution of *snai1*, complete overlap is not always observed. Together, these studies suggest that *snai1* and *mmp15* are similarly expressed in developing valve structures and *Snai1* function is required for *mmp15* expression during EMT stages.

#### *Snai1*, but not MMP15 is sufficient to initiate EMT and promote cell transformation in avian atrioventricular canal explants

Understanding the mechanisms of EC EMT has been greatly enhanced by studies in the chick using collagen I gel explant systems (Bernanke and Markwald, 1982; Person et al., 2005). In the avian model, EC formation is initiated in the looped heart at HH St. 14, and by HH St.18, EMT is active in all cushion sets (Person et al., 2005). Worthy of mention, the EMT inductive signals in the chick appear conserved with the mouse system and include Bmp and Tgfb signaling (Armstrong and Bischoff, 2004; Combs and Yutzey, 2009; Person et al., 2005). To investigate if *Snai1* and MMP15 are sufficient to promote EMT in AVC endothelial cells, we employed a published in vitro collagen I gel explant assay (Bernanke and Markwald, 1982; Mjaatvedt et al., 1987; Runyan and Markwald, 1983). In this assay, HH St.14 AV canals are placed on a 3-dimensional (3D) rat-tail collagen I gel with the endothelial cell layer facing down, allowing cells to migrate onto the surface of the gel (Runyan and Markwald, 1983). With the myocardium intact, subsets of endothelial cells then invade the underlying gel as newly transformed mesenchymal cells (Inai et al., 2008; Mjaatvedt et al., 1987; Runyan and Markwald, 1983). To



**Fig. 2.** Proliferation is increased in endocardial cushions from *Tie2cre;Snai1<sup>fl/+</sup>* mice at E13.5 and cell number is comparable with controls. (A, B) Alcian blue staining on tissue sections from E13.5 *Snai1<sup>fl/+</sup>* (control) and *Tie2cre;Snai1<sup>fl/+</sup>* embryos to indicate AVC valve primordia structures (outlined). (C) Quantitative analysis to show comparable nuclei number within valve primordia of *Tie2cre;Snai1<sup>fl/+</sup>* and control mice at E13.5. (D, E) Phospho-Histone H3 immunoreactivity to detect proliferating cells within valve primordia of *Snai1<sup>fl/+</sup>* control (D) and *Tie2cre;Snai1<sup>fl/+</sup>* (E) embryos at E13.5. (F) Percentage of Phospho-histone H3 positive cells within valve primordia from *Tie2cre;Snai1<sup>fl/+</sup>* mice compared to controls at E10.5 and E13.5.  $n = 4$ , \* $p < 0.05$ , statistical significance compared to controls. IVS, interventricular septum.



**Table 1**


Superarray analysis to show differential gene expression in E10.5 atrioventricular canal regions from *Tie2cre;Snai1<sup>fl/+</sup>* mice. Following analysis, gene expression was normalized to the mean cycle count of *GAPDH*, *Gusb*, *Hsp90ab1*. Fold changes are shown compared to *snai1<sup>fl/+</sup>*.

Gene	Fold change	p value
Emilin1 (elastin microfibril interfacier 1)	0.16 ± 0.05	0.002
Itgb3 (Integrin-βeta 3)	0.37 ± 0.1	0.039
Lamc1 (laminin-gamma 1)	0.39 ± 0.09	0.030
Mmp15	0.27 ± 0.12	0.028
Sparc (secreted protein, acidic, cysteine-rich)	0.11 ± 0.1	0.006
Spp1 (secreted phosphoprotein 1)	0.14 ± 0.13	0.023
Thbs1 (thrombospondin 1)	0.08 ± 0.1	0.022
Timp2 (tissue inhibitor of metalloproteinase 2)	0.18 ± 0.08	0.016


validate the use of the avian system in our study, IHC was performed to determine localization of *Snai1* and *Mmp15* in avian ECs at HHSt.14. As shown in Figs. 4A and B, *Snai1* and *Mmp15* are similarly expressed in endothelial (Figs. 4A, B arrowheads) and mesenchyme (arrows) within the developing cushion. To determine if *Snai1* or *MMP15* promote cell transformation, HH St.14 AVC explants were subjected to *Snai1* gain of function by infecting with a GFP-tagged adenovirus containing full-length FLAG-labeled mouse *Snai1* (AdV-*Snai1*) (Fig. 4E), or a control virus with no insert (AdV-GFP) (Fig. 4D). Exogenous levels of murine *Snai1* following adenoviral infection were confirmed by western blot to detect the FLAG epitope (data not shown). For overexpression experiments, the infection efficiency of the AdV-GFP and AdV-*Snai1* adenoviruses was comparable with an average of 55.8% ± 2.29% cells being infected using AdV-GFP and 53.0% ± 6.45% with AdV-*Snai1*. To investigate the function of *MMP15* during EC EMT, explants were alternatively treated with an exogenous human recombinant

*MMP15* catalytic domain that functions as a constitutively active form of *MMP15* (caMMP15) (Rebustini et al., 2009). Following 48-hour treatment, explants were subjected to IHC to detect transformed αSMA-positive mesenchyme cells that migrate over the surface of the collagen gel away from the original explant site as (indicated by dotted white line) (Figs. 4D, E, G, H). Compared to AdV-GFP controls (Fig. 4D), AdV-*Snai1* treatment (Fig. 4E) significantly increases the number of αSMA positive cells by over 2-fold (Fig. 4F), whereas compared to respective controls, caMMP15 does not promote EMT in HH St.14 AV canal explants (Fig. 4G–H). In addition, increased cell migration in response to AdV-*Snai1* treatment was associated with increased *mmp15* expression (11.83 ± 1.82-fold), as determined by qPCR (Fig. 4J).

To support these studies, and determine if *snai1* or *MMP15* can promote cell transformation at later stages of EC development, ECs from HH St. 25–26 (cE4.5) embryos were removed from the adjacent myocardium, trypsinized and cultured as a 2-dimensional (2D) monolayer. This system allows for minimal cell–cell contact and therefore changes in transformation can be examined in a neutral environment (Lincoln et al., 2006a). Dissociated cells were similarly treated with AdV-*Snai1*, AdV-GFP, caMMP15 or vehicle and following 72 h, changes in expression of mesenchymal (*vimentin*, *fibronectin*, *SMA*) and endothelial (*VE-cadherin*, *claudin1*) cell markers were examined by qPCR (Fig. 4K, L). AdV-*Snai1* treatment leads to increased expression of mesenchymal cell markers *vimentin* (+12.6-fold) and αSMA (+2.67-fold), and associated decreased expression of endothelial cell markers *VE-cadherin* (−4.0-fold) and *claudin1* (−15.68-fold), compared to AdV-GFP controls (Fig. 4K). However, gene expression indicative of cell transformation was not affected with caMMP15 treatment compared to respective vehicle (water) controls (Fig. 4L). These data support a role of *Snai1*, but not *MMP15*, in promoting cell transformation during EC development.



**Fig. 3.** *Mmp15* expression is reduced in endocardial cushions from *Tie2cre;Snai1<sup>fl/+</sup>* mice at E10.5. (A) Superarray qPCR analysis to show decreased *mmp15* expression in AVC regions from E10.5 *Tie2cre;Snai1<sup>fl/+</sup>* mice at E10.5 compared to *snai1<sup>fl/+</sup>* controls.  $p < 0.05$ , statistical significance compared to controls, ( $n = 4$ ). (B, C) Immunohistochemistry to show decreased *mmp15* expression in endothelial (arrowheads) and mesenchymal (arrows) cells of the ECs in *Tie2cre;snai1<sup>fl/+</sup>* mice (C) compared to controls (B). Red staining indicates chondroitin sulfate proteoglycan (CSPG) immunoreactivity to highlight the ECs (B, C), # indicates non-specific immunoreactivity in myocardium. (D) qPCR analysis to show approximate absolute transcript numbers of *snai1* and *mmp15* at mouse (m) embryonic stages (E) 10.5, 12.5 14.5 and post natal (PN) ( $n = 4$ ). (E, F) Co-localization studies reveal similar expression patterns between *Snai1* (green) and *Mmp15* (red) in endothelial (arrowheads) and mesenchyme (arrow) cells within the endocardial cushion at E13.5. EC, endocardial cushion; At, atria; V, ventricle; RV, right ventricle; LV, left ventricle.



**Fig. 4.** Snai1, but not MMP15 promotes initiation of endocardial cushion EMT and cell transformation. (A, B) Immunohistochemistry to show Snai1 (A) and Mmp15 (B) expression in endothelial (arrowheads) and mesenchyme (arrows) cells of the developing EC in the chick at HH St.14. (C) No primary antibody control. Scale bar = 50  $\mu$ m. (D–I) HH St.14 AVC explants on 3D collagen I gels were treated with AdV-GFP (D), AdV-Snai1 (E), vehicle (water) (G) or caMMP15 (H). Scale bar = 200  $\mu$ m. (F, I) Graph to show fold change in the number of  $\alpha$ -SMA positive cells (red) that have migrated away from the original explant site (dotted line) following treatments. Note increased  $\alpha$ -SMA positive cells with AdV-Snai1 treatment. (J) qPCR to show increased *mmp15* expression in AdV-Snai1 treated HH. St. 14 AVC explants compared to AdV-GFP controls. (K, L) qPCR to indicate changes in gene expression of mesenchymal (*vimentin*, *SMA*, *fibronectin1* (*FN1*)) and endothelial (*VE-cadherin* (*VE-cad*) and *Claudin1* (*Cldn1*)) markers in cE4.5 dissociated endocardial cushion cells treated with AdV-Snai1 compared to AdV-GFP controls (K) or caMMP15 compared to vehicle (water) controls (L). Note the increase in mesenchymal gene expression and decrease in endothelial genes with AdV-Snai1, but not caMMP15 treatment.  $n = 5–8$ , \* $p < 0.05$ , compared to respective controls.

#### *Snai1* and MMP15 are sufficient to promote cell invasion and migration in developing endocardial cushions

For EC formation to occur, transformed cells from the overlying endothelial cell layer must invade the cardiac jelly and migrate to their destination within the expanding cushion (Person et al., 2005). To mimic EC cell invasion in vitro and examine if Snai1 and MMP15 play a role in this process, HH St. 14 AVC explants with minimal intact myocardium were placed on 3D collagen I gels and subjected to AdV-Snai1, AdV-GFP, caMMP15 or vehicle treatment. By reconstructing 2D stacks of Z series captured by confocal imaging, we observe that both AdV-Snai1 and caMMP15 treatments increase cell invasion (Figs. 5A–C, E–G), and the distance traveled by invading cells compared to respective controls (Figs. 5A, B, D, E, F, H). In addition, and consistent

with observations in Figs. 4F and I, the number of  $\alpha$ SMA positive cells appears higher with AdV-Snai1, but not caMMP15 treatment. These findings suggest that in ECs, Snai1 and MMP15 play roles in promoting cell invasion during stages of EMT initiation.

The sufficiency of Snai1 and MMP15 to promote migration of transformed mesenchyme cells within the cardiac jelly of developing ECs was examined using cE5.0 AVC explants on 3D collagen I gels. Similar to cell invasion assays, both caMMP15 and AdV-Snai1 treatments increase the area covered by migrating cells on the surface of the collagen I gel, over respective controls (Figs. 6A–D, G). To further investigate the relationship between Snai1 and Mmps during cell migration, explants were treated with the pan-MMP inhibitor GM6001 (1 $\times$ ) (Fig. 6E–F) in the presence of AdV-GFP (Fig. 6E) or AdV-Snai1 (Fig. 6F). Compared to AdV-GFP controls (Fig. 6C), inhibition of


MMP activity (AdV-GFP:MMP Inhib, Fig. 6E) significantly reduces the area covered by migrating cells on the gel surface. Further, MMP inhibition in the presence of AdV-Snai1 (Fig. 6F) attenuates the ability of AdV-Snai1 (Fig. 6D) to promote cell migration in a dose dependent manner (0.2×, 1×, 2×) (Fig. 6D compared to 6F, 6H). These observations suggest that Snai1-mediated cell migration in maturing ECs requires MMP activity.

*caMMP15 treatment rescues attenuated mesenchyme cell migration in murine endocardial cushions with reduced snai1 function*

*Tie2cre;Snai1<sup>fl/+</sup>* mice display defects in cell transformation (Fig. 1F). To determine if reduced *snai1* function also affects cell migration, AVC regions isolated from E11.5 *Snai1<sup>fl/fl</sup>* mice were cultured on 3D collagen I gels and infected with AdV-Cre resulting in a 2.88-fold decrease in *snai1* expression (Fig. 7F). Compared to AdV-GFP controls (Fig. 7A), AdV-Cre treatment significantly reduces cell migration (Figs. 7A, B, E), associated with a 4-fold decrease in *mmp15* (Fig. 7F). However, cell migration defects are no longer observed when explants were co-treated with caMMP15 (Fig. 7B compared to 7D). Therefore suggesting that caMMP15 treatment is sufficient to rescue attenuated cell migration defects observed in ECs following reduced *snai1* function.


*Snai1 binds and regulates E-box-rich sequences within the promoter region of mmp15*

There are increasing data to suggest that Snai1 may regulate MMP function in several cell types to promote motility (Joseph et al., 2009; Ota et al., 2009; Rowe et al., 2009), however molecular interactions have not been reported. Snail family members regulate transcription via interactions with E-box binding sites (CANNTG) on target gene DNA. Within 6000 bp upstream of the ATG transcription start site of the murine *mmp15* gene, a total of six canonical E-box sites have been identified denoted within three regions (B–D), each containing two E-boxes (Fig. 8A). Of note, three of the six E-box sites are conserved with rat and four with human *mmp15* promoter regions (indicated in Fig. 8A). Snai1 binding to regions B, C and/or D (Fig. 8A) in *mmp15* was assessed using chromatin immunoprecipitation (ChIP) in whole E11.5 mouse hearts. Region A was included as a negative control as it does not contain canonical E-box sites. Cross-linked DNA/protein complexes immunoprecipitated with Snai1 antisera demonstrate significant enrichment of binding within B, C and D regions of *mmp15* compared to IgG controls. In contrast, enrichment was not observed in region A (Fig. 8B). To further assess the functionality of E-boxes within regions B, C and D, luciferase assays were



**Fig. 5.** AdV-Snai1 and caMMP15 treatments promote cell migration in HH St. 14 AVC explants. (A, B, E, F) HH St.14 AVC explants were placed on 3D collagen I gels and treated with AdV-GFP (A), AdV-Snai1 (B), vehicle (water) (E) or caMMP15 (F). Scale bars in A, B = 200  $\mu$ m, E, F = 100  $\mu$ m. Confocal microscopy and Z-stack reconstruction (A, B, E, F) were used to determine the fold change in the number of cells invading the 3D collagen I gel (C, G), and the average maximum distance of invasion (D, H) in AdV-Snai1 (B) and caMMP15 (F) treated cultures compared to respective controls (A, E). Immunohistochemistry indicates  $\alpha$ -SMA positive cells (red) and DAPI indicates nuclei (blue). Note increased invasion with AdV-Snai1 and caMMP15 treatments.  $n = 5$ , \* $p < 0.05$ , statistical significance compared to respective controls.






**Fig. 6.** Loss of MMP activity attenuates *snai1*-mediated mesenchyme cell migration in developing endocardial cushions in vitro. (A–D) cE5.0 AVC collagen I explants treated with vehicle (water) (A), caMMP15 (B), AdV-GFP (C) AdV-Snai1 (D), or AdV-GFP (E) or AdV-Snai1 (F) in the presence of the MMP inhibitor (MMP Inhib) GM6001. (G) Quantitation to show fold change in cell migration area on the surface of the collagen I gel (dotted line) following each treatment \* $p < 0.05$ , statistical significance compared to respective controls, # $p < 0.05$ , and significance compared to AdV-Snai1. (H) Dose-response effects of GM6001 on cell migration in the presence of AdV-Snai1.  $n = 5–8$ , \* $p < 0.05$  compared to 0.2X treatment.

performed in COS-7 cells using pGL3 constructs containing ~1 kb amplified sequences targeting each region (pGL3-mmp15B (970 bp), pGL3-mmp15C (1006 bp), and pGL3-mmp15D (973 bp)). 6 h after transfection with respective pGL3-mmp15 constructs, cells were further infected with AdV-GFP or AdV-Snai1 (as used in Figs. 4–6). Despite, enrichment observed by ChIP, AdV-Snai1 infection of cells transfected with pGL3-mmp15B had no significant effect on luciferase activity of Region B, compared to AdV-GFP:pGL3mmp15B controls (Fig. 3C). Worthy of mention, significant luciferase activity was also

not observed in AdV-infected cells co-transfected with empty vectors (data not shown). However, consistent with ChIP findings, AdV-Snai1 infection significantly increased transactivation of mmp15 region C (pGL3-mmp15C) ( $38.49\% \pm 8.73\%$ ) over AdV-GFP, with trends of activation also observed with Region D (pGL3-mmp15D) ( $29.0\% \pm 10.79\%$ ,  $p = 0.3$ ).

Previous studies have shown that Snail and E2A (E47/E12) family members regulate activity of common target genes through interaction with specific E-box sites within the proximal promoter (Bolos



**Fig. 7.** caMMP15 treatment rescues attenuated cell migration defects observed in AVC explants with *Snai1* knockdown. (A–F) E11.5 AVC collagen I explants from *snai1<sup>fl/fl</sup>* mice treated with AdV-GFP:DMSO (A), AdV-Cre:DMSO (B), AdV-GFP:caMMP15 (C) or AdV-Cre:caMMP15 (D). (E) Quantification to show fold change in the area covered by migrating cells on the surface of the collagen I gel compared to AdV-GFP:DMSO treatment (\* $p < 0.05$ ). Note decreased migration with AdV-Cre:DMSO treatment compared to AdV-GFP:DMSO, and rescue with the addition of caMMP15 (AdV-Cre:caMMP15) to levels comparable with AdV-GFP:DMSO. (F) qPCR to show decreased *Snai1* expressed with AdV-Cre infection in explants from *snai1<sup>fl/fl</sup>* mice, in addition to downregulation of *mmp15*.  $n = 4–6$ , \* $p < 0.05$  compared to AdV-GFP.


et al., 2003; Cano et al., 2000; Peinado et al., 2004). To determine if E47 or E12 function effects *Snai1*-mediated transactivation of *mmp15*, luciferase assays were repeated in the presence of pcDNA-E47 or pcDNA-E12. Although E2A family members alone have been shown to act as transcriptional activators (Takahashi et al., 2004) and repressors (Battile et al., 2000; Cano et al., 2000; Perez-Moreno et al., 2001), co-transfection of pGL3-mmp15B, pGL3-mmp15C or pGL3-mmp15D with pcDNA-E47 or pcDNA-E12 in the presence of AdV-GFP, had no effect on *mmp15* activity (data not shown). However, co-transfection of pcDNA-E47 in the presence of AdV-*Snai1* significantly repressed pGL3-mmp15B ( $-70.82\% \pm 19.77\%$ ), pGL3-mmp15C ( $-39.09\% \pm 0.46\%$ ) and pGL3-mmp15D ( $-48.40\% \pm 17.07\%$ ). Co-transfection with pcDNA-E12 had no significant effect on AdV-*Snai1*-mediated *mmp15* activity (data not shown). Collectively these studies reveal that *Snai1* physically interacts and activates specific E-box-rich promoter regions within *mmp15*. Further, we provide evidence to suggest that E47 function plays an important role in *Snai1*-mediated regulation of *mmp15*.

## Discussion

In developing ECs, the EMT program converts endothelial cells into migratory mesenchymal cells through sequential steps that require many phenotypic changes (Barrallo-Gimeno and Nieto, 2005; Thiery et al., 2009). The transcription factor *Snai1* has previously been shown to be indispensable for EMT in many tissues during embryonic development and pathological processes (Nieto, 2009; Thiery et al., 2009). Despite *snai1* expression correlating with EMT activity in developing valve structures (Liebner et al., 2004; Luna-Zarita et al., 2010; Meadows et al., 2009; Nath et al., 2008; Wang et al., 2005), a direct role in EC formation has not previously been reported. This is likely due to the premature lethality of *Snai1*<sup>-/-</sup> embryos prior to cardiogenesis (Carver et al., 2001). To address this limitation, we performed in vivo studies using viable *Tie2cre;Snai1<sup>fl/+</sup>* mice, in parallel with gain and loss of *Snai1* function in AVC explants in vitro. The goal of this study was to use these previously established systems to reveal new insights into the role of *Snai1* for cell transformation, invasion and migration in developing ECs in the embryonic heart.

Prior to EMT, *Snai1* is highly expressed in endothelial cells of the AV canal and expression is maintained in this cell layer throughout EC formation and valvulogenesis (Figs. 1A, B, 4A) (G. Tao, Unpublished). During EMT, *Snai1* expression is also observed in transformed mesenchyme cells, however expression is downregulated as these cells differentiate during remodeling stages (Figs. 1A, B, 4A) (Lincoln et al., 2006b). In this study we show that *Snai1* is important in many sequential steps during EMT beginning with the early transformation of a subset of cardiac endothelial cells into mesenchyme cells, and proceeding mesenchyme cell invasion and migration. Further, we show that MMP activity is required for *Snai1*-mediated mesenchyme cell migration and more specifically, MMP15 activity is sufficient to rescue migratory phenotypes observed in ECs with targeted *snai1* knockdown. Together, findings from this study suggest that *Snai1* is an important regulator of EC formation and directly binds and regulates *mmp15* to promote cell motility during this process.

*Snai1*-mediated signaling pathways in EMT have been extensively studied and therefore parallel mechanisms in the developing heart are considered. Several known upstream regulators of *Snai1* are expressed during cardiogenesis (Luna-Zarita et al., 2010; Molin et al., 2003; Niessen et al., 2008; Thiery et al., 2009) and manipulation studies of Notch1, Tgfb3s and Bmps, their receptors or intermediate signaling kinases affect *snai1* expression in developing cushions (Luna-Zarita et al., 2010; Meadows et al., 2009; Wang et al., 2005). Therefore *Snai1*-induced EC EMT is likely initiated by these established signaling pathways in vivo. Downstream, we can speculate that *Snai1* promotes EMT in developing cushions through mechanisms previously described in other non-cardiac tissues including repression of cell adhesion genes (Cano et al., 2000; Liebner et al., 2004; Meadows et al., 2009; Nath et al., 2008) and activation of mesenchymal markers (Battile et al., 2000; Cano et al., 2000; Guaita et al., 2002; Ikenouchi et al., 2003; Person et al., 2005). In *Tie2cre;Snai1<sup>fl/+</sup>* mice, it is likely that these signaling pathways are abrogated as a result of reduced *snai1* function, leading to hypocellular ECs. In addition to attenuated transformation, it is plausible that deficient mesenchyme cell motility and/or imbalanced cell survival also contribute to this phenotype. Indeed, our data supports a positive role for *Snai1* in cell invasion and migration in developing ECs, however changes in cell proliferation



**Fig. 8.** Snai1 binds and regulates E-box rich regions within the promoter region of *mmp15* in whole mouse hearts. (A) Schematic diagram to illustrate the location of six E-box sites (black solid bars) within three regions (B, C, D) of *mmp15* at indicated base pair positions upstream of the ATG start site (+1). Region A is included as a negative control and does not contain canonical E-box sites. Gray arrows indicate the location of PCR primers used to determine enrichment in DNA/protein complexes following Snai1 pull down. \*, # indicate conservation of E-box sites with human (\*) and rat (#) sequences. (B) qPCR to show significant enrichment of Snai1 binding to regions B, C and D within the *mmp15* promoter following co-immunoprecipitation using whole E11.5 mouse hearts, over IgG controls. Note insignificant enrichment in region A that does not contain E-box sites. \*p<0.05 compared to IgG controls (n = 3). (C) Luciferase assays to show significant increased activity of pGL3-mmp15C in the presence of AdV-Snai1, compared to respective AdV-GFP controls. Co-transfection with pcDNA-E47, represses luciferase activity of pGL3-mmp15B, pGL3-mmp15C and pGL3-mmp15D in the presence of AdV-Snai1, but not AdV-GFP. Data is represented as a fold change in luciferase activity normalized to *Renilla* in AdV-Snai1 infected cells co-transfected with indicated plasmids compared to parallel AdV-GFP infected controls. n = 3–4, \*p<0.05. (D) Mmp15 sequence of Regions B, C and D to show predicted transcription factor binding sites, based on Genomatix analysis with predicted 'matrix similarity' >0.90. The core binding consensus sequences are indicated: AP1F, Activating Protein 1; CEBP, CCAAT/Enhancer Binding Protein; HOXF, Hox Family; PAX8, Pax 2/5/8 binding site; STAT, Signal transducer and activator of transcription 1; ZFXH, Two-handed zinc finger homeodomain transcription factors; KLFS, Krueppel like transcription factors; BCDF, Bicoid-like homeodomain transcription factors; NEUR, NeuroD, beta2, HLH domain; FKND, Fork head domain factor; HAND, Twist subfamily of bHLH factors; MEF3, myocyte-specific enhancing factor 3; SMAD, SMAD family; NF1F, nuclear factor 1; NFAT, Nuclear Factor of activated T-cells; YY1F, Activator/repressor binding to transcriptional initiation site; MyoD, myoblast determining factors; HEAT, Heat shock factors; SP1F, GC-Box factors SP1/GC; ZF02, C2H2 Zinc finger transcription factors 2.

or apoptosis were not observed in *Tie2cre;Snai1<sup>fl/+</sup>* mice at E10.5. In contrast, cell proliferation was enhanced at E13.5 and levels were sufficient to increase mesenchyme cell number to levels comparable with controls. Compensation of EC cellularity was similarly reported in *Snai2<sup>-/-</sup>* mice that exhibit hypocellular cushions at E9.5 but not E10.5, and attributed to increased *snai1* expression (Niessen et al., 2008). However, increased expression of Snai1 family members were not detected in *Tie2cre;Snai1<sup>fl/+</sup>* mice (data not shown), consistent with observations reported in *snai1<sup>-/-</sup>* mice (Carver et al., 2001). Therefore it is likely that alternative mechanisms promote the compensatory proliferative response in ECs from mice with reduced *snai1* function.

In addition to developmental processes, Snai1-mediated EMT is active in many cancer cell lines and high expression levels correlative with increased cell migration and metastasis (Thiery et al., 2009; Wu and Zhou, 2010). A recent study suggested that this pathologic function of *snai1* is mediated through induction of MT-MMPs, that when activated, recapitulate *snai1*'s ability to degrade basement membranes and promote cancer cell migration (Ota et al., 2009). In this study, we present several lines of evidence to suggest that in addition to disease, activated MT-MMPs also promote cell motility, but not transformation,

in the embryonic heart during EC development. Further, we identify *mmp15* (or MT2-MMP) as a direct target gene of Snai1, and a positive regulator of mesenchyme cell invasion and migration. This finding extends the current repertoire of known target genes regulated by Snai1 during EMT beyond cell transformation processes (Batlle et al., 2000; Cano et al., 2000; Guaita et al., 2002; Ikenouchi et al., 2003; Person et al., 2005).

In ECs from *Tie2cre;Snai1<sup>fl/+</sup>* mice, *mmp15* was the only MMP family member whose expression was affected by reduced *snai1* function, although decreased trends of the MMP15 target gene *mmp9* were also observed (data not shown). The widespread protein localization of *mmp15* throughout the ECs suggests that this mmp family member may target ECM substrates in both endothelial and mesenchymal cells. Type IV collagen is a known substrate of MMP15 in basement membranes (Hotary et al., 2000; Rebutini et al., 2009) and its degradation in endothelial cells lining the AV canal and OFT regions is important for EMT and EC formation (Song et al., 2000). Therefore leading to the conclusion that *mmp15* may facilitate endothelial cell delamination, independent of transformation in developing ECs. Mmp15's function in mesenchymal cells is less speculative and its activity correlates



with increased mesenchyme cell invasion and migration in AV canal explants. Like *mmp15*, other family members including *mmp2* and *9* are also highly expressed in mesenchyme cells during EC EMT, where they facilitate ECM degradation to promote mesenchymal cell motility through the hyaluronan-rich cardiac jelly (Rupp et al., 2008; Shelton and Yutzey, 2007). The observation that *Snai1* directly binds and activates *mmp15* is consistent with a recent study showing that *Snai2* (slug) binds and regulates activity of another family member, *membrane-type 4 MMP* (Huang et al., 2009). Findings from this current study have revealed a new role for *snai1* as a transcriptional activator of *mmp15* to promote cell migration during EC EMT.

The observation that *Snai1* acts as a transcriptional activator of *mmp15* is somewhat surprising as despite emerging evidence to support this function (Batlle et al., 2000; Cano et al., 2000; Guaita et al., 2002; Hwang et al., 2011; Ikenouchi et al., 2003; Person et al., 2005), *Snai1* is more commonly known as a repressor (Nieto, 2009). In our system, *Snai1* increases *mmp15* transactivity by 38%, which could be considered a subtle, albeit significant, difference. As this study is one of the first to show direct transactivation of target genes by *Snai1*, it is not clear if the addition of co-activators (or removal of co-repressors) could increase *mmp15* activity above this level. In contrast to AdV-*Snai1* treatment, E47 alone has no effect on *mmp15*, yet E47 in the presence of AdV-*Snai1*, leads to repression. As previous studies have shown that *Snai1* and E47 regulate common target genes through interaction with specific E-boxes (Bolos et al., 2003) (Peinado et al., 2004; Perez-Moreno et al., 2001), we speculate that overexpressed E47 binds with no functional effect, to prevent *Snai1* interaction and transactivation of *mmp15*. This mechanism may also in part explain the subtle increase in *mmp15* activity with AdV-*Snai1* treatment: as endogenous E47 competes with *Snai1* for E-box binding. This competition may also be dependent on differential binding affinities of *Snai1* and E47 on the same target genes (Bolos et al., 2003). Although this might explain the lost activation of *mmp15* by *Snai1*, the mechanism in which *Snai1* and E47 cooperate to repress *mmp15* is not clear, but likely requires recruitment of co-repressor machinery at the putative E-box sites. Our studies using the in vivo mouse and in vitro chick models, strongly suggest that *Snai1* positively regulates *mmp15* in these systems, therefore suggesting that endogenous E2A expression levels are low at this time. However, it remains unknown how *Snai1*-E2A work together to regulate *mmp15* during post-EMT stages when cell motility is less active.

There is increasing evidence that adult heart valve disease has origins in embryonic development (Combs and Yutzey, 2009). *Tie2cre; Snai1<sup>fl/+</sup>* mice display EC defects by E10.5, although heterozygous embryos recover by E13.5 and adult valve morphology is grossly indistinct from control animals. Therefore alternative approaches are needed to thoroughly examine the requirement of *Snai1* during EC development, for adult cardiac function. Nonetheless this study provides new insights into the regulatory functions of *Snai1* through *mmp15*, to form the pool of precursor cells within the ECs that later give rise to the diversified mature valve structures (Lincoln et al., 2004). Worthy of mention, *snai1* expression is detectable at post-EMT stages in endothelial cells that overlay the maturing valve leaflets (G. Tao, Unpublished). It remains unknown why valve endothelial cells at these later stages do not undergo EMT in vivo, even in the presence of *Snai1*. As discussed above in the context of *mmp15*, this is likely dependent upon the maturation of VECs during valvulogenesis and therefore related to the absence (or presence) of some *Snai1* targets or co-factors, some potential candidates are indicated in Fig. 8D (Barrallo-Gimeno and Nieto, 2005). However, as treatment strategies for degenerative heart valve disease are limited, it would be beneficial to determine if *snai1* can provide a genetic 'cue' to reactivate developmental EMT programs in post-natal valves as a means to maintain or replace the interstitial valve cell population during life. During later stages of valvulogenesis *Snai1* may have additional functions, and based upon its repressive function on ECM genes (Seki et al., 2003) and positive regulation of *mmp* activity (this study), it is plausible that *Snai1* is involved in

valve remodeling (Lincoln et al., 2006b). Further, alterations in the regulation of *Snai1* during this process may have implications in degenerative valve disease characterized by pathological remodeling and associated with increased *MMP-2*, *-9* and *-13* expression (Kaden et al., 2004; Rabkin et al., 2001; Soini et al., 2001). In conclusion, this current study has revealed new information into the role of *snai1* during early heart valve formation that may provide insights into mechanisms of congenital heart valve disease that result from defects in EC formation.

## Acknowledgments

We thank Harriet Hammond for editorial assistance, Dr. Nakamura for kindly providing DNA constructs, and Drs. Jacqueline Peacock, George McNamara and Yuhui Wen for scientific and technical support. This work was supported by NIH/NHLBI (1R01HL091878-JL, HD034883-TG) and AHA Predoctoral Fellowship (10PRE4360052-GT).

## References

- Armstrong, E.J., Bischoff, J., 2004. Heart valve development: endothelial cell signaling and differentiation. *Circ. Res.* 95, 459–470.
- Barrallo-Gimeno, A., Nieto, M.A., 2005. The *Snail* genes as inducers of cell movement and survival: implications in development and cancer. *Development* 132, 3151–3161.
- Batlle, E., Sancho, E., Franci, C., Dominguez, D., Monfar, M., Baulida, J., Garcia De Herreros, A., 2000. The transcription factor *snail* is a repressor of E-cadherin gene expression in epithelial tumour cells. *Nat. Cell Biol.* 2, 84–89.
- Bernanke, D.H., Markwald, R.R., 1982. Migratory behavior of cardiac cushion tissue cells in a collagen-lattice culture system. *Dev. Biol.* 91, 235–245.
- Bolos, V., Peinado, H., Perez-Moreno, M.A., Fraga, M.F., Esteller, M., Cano, A., 2003. The transcription factor *Slug* represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with *Snail* and E47 repressors. *J. Cell Sci.* 116, 499–511.
- Cano, A., Perez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., del Barrio, M.G., Portillo, F., Nieto, M.A., 2000. The transcription factor *snail* controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat. Cell Biol.* 2, 76–83.
- Carver, E.A., Jiang, R., Lan, Y., Oram, K.F., Gridley, T., 2001. The mouse *snail* gene encodes a key regulator of the epithelial-mesenchymal transition. *Mol. Cell Biol.* 21, 8184–8188.
- Combs, M.D., Yutzey, K.E., 2009. Heart valve development: regulatory networks in development and disease. *Circ. Res.* 105, 408–421.
- de Lange, F.J., Moorman, A.F., Anderson, R.H., Manner, J., Soufan, A.T., de Gier-de Vries, C., Schneider, M.D., Webb, S., van den Hoff, M.J., Christoffels, V.M., 2004. Lineage and morphogenetic analysis of the cardiac valves. *Circ. Res.* 95, 645–654.
- Funato, N., Ohtani, K., Ohyama, K., Kuroda, T., Nakamura, M., 2001. Common regulation of growth arrest and differentiation of osteoblasts by helix-loop-helix factors. *Mol. Cell Biol.* 21, 7416–7428.
- Guaita, S., Puig, I., Franci, C., Garrido, M., Dominguez, D., Batlle, E., Sancho, E., Dedhar, S., De Herreros, A.G., Baulida, J., 2002. *Snail* induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. *J. Biol. Chem.* 277, 39209–39216.
- Hinton Jr., R.B., Lincoln, J., Deutsch, G.H., Osinska, H., Manning, P.B., Benson, D.W., Yutzey, K.E., 2006. Extracellular matrix remodeling and organization in developing and diseased aortic valves. *Circ. Res.* 98, 1431–1438.
- Hoffman, J.I.E., Kaplan, S., 2002. The incidence of congenital heart disease. *J. Am. Coll. Cardiol.* 39, 1890–1900.
- Hotary, K., Allen, E., Punturieri, A., Yana, I., Weiss, S.J., 2000. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. *J. Cell Biol.* 149, 1309–1323.
- Huang, C.H., Yang, W.H., Chang, S.Y., Tai, S.K., Tzeng, C.H., Kao, J.Y., Wu, K.J., Yang, M.H., 2009. Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis. *Neoplasia* 11, 1371–1382.
- Hwang, W.L., Yang, M.H., Tsai, M.L., Lan, H.Y., Su, S.H., Chang, S.C., Teng, H.W., Yang, S.H., Lan, Y.T., Chiou, S.H., Wang, H.W., 2011. *SNAIL* regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. *Gastroenterology* 141 279–291 e275.
- Ikenouchi, J., Matsuda, M., Furuse, M., Tsukita, S., 2003. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by *Snail*. *J. Cell Sci.* 116, 1959–1967.
- Inai, K., Norris, R.A., Hoffman, S., Markwald, R.R., Sugi, Y., 2008. BMP-2 induces cell migration and periostin expression during atrioventricular valvulogenesis. *Dev. Biol.* 315, 383–396.
- Jiang, R., Lan, Y., Norton, C.R., Sundberg, J.P., Gridley, T., 1998. The *Slug* gene is not essential for mesoderm or neural crest development in mice. *Dev. Biol.* 198, 277–285.
- Joseph, M.J., Dangi-Garimella, S., Shields, M.A., Diamond, M.E., Sun, L., Kobliński, J.E., Munshi, H.G., 2009. *Slug* is a downstream mediator of transforming growth factor-beta1-induced matrix metalloproteinase-9 expression and invasion of oral cancer cells. *J. Cell. Biochem.* 108, 726–736.

- Kaden, J.J., Vocke, D.C., Fischer, C.S., Grobholz, R., Brueckmann, M., Vahl, C.F., Hagl, S., Haase, K.K., Dempfle, C.E., Borggrefe, M., 2004. Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis. *Z. Kardiol.* 93, 124–130.
- Kisanuki, Y.Y., Hammer, R.E., Miyazaki, J., Williams, S.C., Richardson, J.A., Yanagisawa, M., 2001. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. *Dev. Biol.* 230, 230–242.
- Liebner, S., Cattelino, A., Gallini, R., Rudini, N., Iurlaro, M., Piccolo, S., Dejana, E., 2004. Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. *J. Cell Biol.* 166, 359–367.
- Lincoln, J., Alfieri, C.M., Yutzey, K.E., 2004. Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. *Dev. Dyn.* 230, 239–250.
- Lincoln, J., Alfieri, C.M., Yutzey, K.E., 2006a. BMP and FGF regulatory pathways control cell lineage diversification of heart valve precursor cells. *Dev. Biol.* 292, 292–302.
- Lincoln, J., Lange, A.W., Yutzey, K.E., 2006b. Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. *Dev. Biol.* 294, 292–302.
- Lincoln, J., Kist, R., Scherer, G., Yutzey, K.E., 2007. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. *Dev. Biol.* 305, 120–132.
- Lloyd-Jones, D., Adams, R.J., Brown, T.M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T.B., Ford, E., Furie, K., Gillespie, C., Go, A., Greenlund, K., Haase, N., Hailpern, S., Ho, P.M., Howard, V., Kissela, B., Kittner, S., Lackland, D., Lisabeth, L., Marelli, A., McDermott, M.M., Meigs, J., Mozaffarian, D., Mussolino, M., Nichol, G., Roger, V.L., Rosamond, W., Sacco, R., Sorlie, P., Thom, T., Wasserthiel-Smoller, S., Wong, N.D., Wylie-Rosett, J., 2010. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. *Circulation* 121, e46–e215.
- Lomeli, H., Starling, C., Gridley, T., 2009. Epiblast-specific Snai1 deletion results in embryonic lethality due to multiple vascular defects. *BMC Res. Notes* 2, 22.
- Luna-Zurita, L., Prados, B., Grego-Bessa, J., Luxan, G., del Monte, G., Benguria, A., Adams, R.H., Perez-Pomares, J.M., de la Pompa, J.L., 2010. Integration of a Notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine cardiac valve formation. *J. Clin. Invest.* 120, 3493–3507.
- Martinez-Estrada, O.M., Culleres, A., Soriano, F.X., Peinado, H., Bolos, V., Martinez, F.O., Reina, M., Cano, A., Fabre, M., Vilaro, S., 2006. The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. *Biochem. J.* 394, 449–457.
- Meadows, K.N., Iyer, S., Stevens, M.V., Wang, D., Shechter, S., Perruzzi, C., Camenisch, T.D., Benjamin, L.E., 2009. Akt promotes endocardial-mesenchyme transition. *J. Angiogenesis Res.* 1, 2.
- Mjaatvedt, C.H., Lepera, R.C., Markwald, R.R., 1987. Myocardial specificity for initiating endothelial-mesenchymal cell transition in embryonic chick heart correlates with a particulate distribution of fibronectin. *Dev. Biol.* 119, 59–67.
- Molin, D.G., Bartram, U., Van der Heiden, K., Van Iperen, L., Speer, C.P., Hierck, B.P., Poelmann, R.E., Gittenberger-de-Groot, A.C., 2003. Expression patterns of Tgfbeta1-3 associate with myocardialisation of the outflow tract and the development of the epicardium and the fibrous heart skeleton. *Dev. Dyn.* 227, 431–444.
- Murray, S.A., Carver, E.A., Gridley, T., 2006. Generation of a Snail1 (Snai1) conditional null allele. *Genesis* 44, 7–11.
- Murray, S.A., Oram, K.F., Gridley, T., 2007. Multiple functions of Snail family genes during palate development in mice. *Development* 134, 1789–1797.
- Nath, A.K., Brown, R.M., Michaud, M., Sierra-Honigsmann, M.R., Snyder, M., Madri, J.A., 2008. Leptin affects endocardial cushion formation by modulating EMT and migration via Akt signaling cascades. *J. Cell Biol.* 181, 367–380.
- Niessen, K., Fu, Y., Chang, L., Hoodless, P.A., McFadden, D., Karsan, A., 2008. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. *J. Cell Biol.* 182, 315–325.
- Nieto, M.A., 2009. Epithelial-mesenchymal transitions in development and disease: old views and new perspectives. *Int. J. Dev. Biol.* 53, 1541–1547.
- Ota, I., Li, X.Y., Hu, Y., Weiss, S.J., 2009. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. *Proc. Natl. Acad. Sci. U.S.A.* 106, 20318–20323.
- Peacock, J.D., Lu, Y., Koch, M., Kadler, K.E., Lincoln, J., 2008. Temporal and spatial expression of collagens during murine atrioventricular heart valve development and maintenance. *Dev. Dyn.* 237, 3051–3058.
- Peacock, J.D., Levay, A.K., Gillaspie, D.B., Tao, G., Lincoln, J., 2010. Reduced sox9 function promotes heart valve calcification phenotypes in vivo. *Circ. Res.* 106, 712–719.
- Peinado, H., Marin, F., Cubillo, E., Stark, H.J., Fusenig, N., Nieto, M.A., Cano, A., 2004. Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. *J. Cell Sci.* 117, 2827–2839.
- Perez-Moreno, M.A., Locascio, A., Rodrigo, I., Dhondt, G., Portillo, F., Nieto, M.A., Cano, A., 2001. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. *J. Biol. Chem.* 276, 27424–27431.
- Person, A.D., Klewer, S.E., Runyan, R.B., 2005. Cell biology of cardiac cushion development. *Int. Rev. Cytol.* 243, 287–335.
- Rabkin, E., Aikawa, M., Stone, J.R., Fukumoto, Y., Libby, P., Schoen, F.J., 2001. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. *Circulation* 104, 2525–2532.
- Rebustini, I.T., Myers, C., Lassiter, K.S., Surmak, A., Szabova, L., Holmbeck, K., Pedchenko, V., Hudson, B.G., Hoffman, M.P., 2009. MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. *Dev. Cell* 17, 482–493.
- Romano, L.A., Runyan, R.B., 1999. Slug is a mediator of epithelial-mesenchymal cell transformation in the developing chicken heart. *Dev. Biol.* 212, 243–254.
- Rowe, R.G., Li, X.Y., Hu, Y., Saunders, T.L., Virtanen, I., Garcia de Herreros, A., Becker, K.F., Ingvarsen, S., Engelholm, L.H., Bommer, G.T., Fearon, E.R., Weiss, S.J., 2009. Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. *J. Cell Biol.* 184, 399–408.
- Runyan, R.B., Markwald, R.R., 1983. Invasion of mesenchyme into three-dimensional collagen gels: a regional and temporal analysis of interaction in embryonic heart tissue. *Dev. Biol.* 95, 108–114.
- Rupp, P.A., Visconti, R.P., Czirok, A., Cheresch, D.A., Little, C.D., 2008. Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. *Mol. Biol. Cell* 19, 5529–5540.
- Seki, K., Fujimori, T., Savagner, P., Hata, A., Aikawa, T., Ogata, N., Nabeshima, Y., Kaechoong, L., 2003. Mouse Snail family transcription repressors regulate chondrocyte, extracellular matrix, type II collagen, and aggrecan. *J. Biol. Chem.* 278, 41862–41870.
- Shelton, E.L., Yutzey, K.E., 2007. Tbx20 regulation of endocardial cushion cell proliferation and extracellular matrix gene expression. *Dev. Biol.* 302, 376–388.
- Soini, Y., Satta, J., Maatta, M., Autio-Harmainen, H., 2001. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. *J. Pathol.* 194, 225–231.
- Song, W., Jackson, K., McGuire, P.G., 2000. Degradation of type IV collagen by matrix metalloproteinases is an important step in the epithelial-mesenchymal transformation of the endocardial cushions. *Dev. Biol.* 227, 606–617.
- Srivastava, D., 2000. Congenital heart defects: trapping the genetic culprits. *Circ. Res.* 86, 917–918.
- Takahashi, E., Funato, N., Higashihori, N., Hata, Y., Gridley, T., Nakamura, M., 2004. Snail regulates p21(WAF/CIP1) expression in cooperation with E2A and Twist. *Biochem. Biophys. Res. Commun.* 325, 1136–1144.
- Thiery, J.P., Acloque, H., Huang, R.Y., Nieto, M.A., 2009. Epithelial-mesenchymal transitions in development and disease. *Cell* 139, 871–890.
- Wang, J., Sridurongrit, S., Dudas, M., Thomas, P., Nagy, A., Schneider, M.D., Epstein, J.A., Kaartinen, V., 2005. Atrioventricular cushion transformation is mediated by ALK2 in the developing mouse heart. *Dev. Biol.* 286, 299–310.
- Wu, Y., Zhou, B.P., 2010. Snail: More than EMT. *Cell Adh. Migr.* 4.